The Search for Exceptional Genomes
Antonio Regalado (Technology Review) $REGN
Yes, there are good secondary offerings in biotech
Brad Loncar (Loncar Blog) $RCPT $LXRX
A Drug Regrew A Little Girl's Missing Bones. How Much Should That Cost?
Matthew Herper (Forbes) $ALXN
NIH and FDA Toughen Rules for Reporting Clinical Trial Results
Ed Silverman (Pharmalot / WSJ)
Company's Compassion Leads to Clinical Hold on Experimental Drug
Alec Gaffney (Regulatory Focus / RAPS) $CYTR
A Billion Here, A Billion There: The Cost Of Making A Drug Revisited
Bruce Booth (Life Sci VC)
Why I Got My Colonoscopy--And You Should, Too
David Kroll (Forbes)
A Refresher on Net Present Value
Amy Gallo (Harvard Business Review)
Antonio Regalado (Technology Review) $REGN
Yes, there are good secondary offerings in biotech
Brad Loncar (Loncar Blog) $RCPT $LXRX
A Drug Regrew A Little Girl's Missing Bones. How Much Should That Cost?
Matthew Herper (Forbes) $ALXN
NIH and FDA Toughen Rules for Reporting Clinical Trial Results
Ed Silverman (Pharmalot / WSJ)
Company's Compassion Leads to Clinical Hold on Experimental Drug
Alec Gaffney (Regulatory Focus / RAPS) $CYTR
A Billion Here, A Billion There: The Cost Of Making A Drug Revisited
Bruce Booth (Life Sci VC)
Why I Got My Colonoscopy--And You Should, Too
David Kroll (Forbes)
A Refresher on Net Present Value
Amy Gallo (Harvard Business Review)
RSS Feed
